Report touts potential of wind power for N.C.
A science panel advising Gov. Beverly Perdue on offshore energy development says oil and gas drilling is unlikely in waters within North Carolina's authority, but the coast has some of the best East Coast locations for wind power.
Green areas are possible offshore wind power lease sites
Cisco CEO: 'Good progress but a long way to go ...'
In an earnings conference call, Cisco Chairman and Chief Executive Officer John Chambers says the company's rebound from some bad quarters is "still in the early stages."
John Chambers
Apple's new iPad to premier in early March, WSJ says
What will it feature? "A device similar in form factor to the iPad 2, but running a much faster chip, sporting an improved graphics processing unit, and featuring a 2048×1536 Retina Display -- or something close to it," reports the All Things Digital blog.
UNC, Duke team up off the court in 'Game of Life'
Bitter rivals in basketball, the two universities collaborate on numerous educational, medical and research efforts to help make the world a better place. They are partners in the "Game of Life" tournament.
Duke, UNC are partners - off the court
Diagnostic labs in High Point to add up to 500 jobs
"High Point was a natural fit for our expansion," Solstas Chief Executive David Weavil says. "Simply put, the energy and experience of the medical workforce here is exceptional and meets our needs for a best-in-class organization."
Durham stem cell firm Aldagen sold for up to $40M
Regenerative medicine company Cytomedix has acquired the venture-capital backed company in a $16 million stock deal plus millions more in stock options. Aldagen investors include Intersouth and Aurora Funds.
A purified STEM cell
Good days are back at Cisco: Earnings rebound, hiring resumes
Cost-cutting has restored investor confidence in Cisco, and the company looks set to expand again. After shedding nearly 10,000 jobs last year, Cisco added a net 400 employees in the latest quarter. Chief Financial Officer Frank Calderone said the hires were mainly in the services arm, and were partly offset by the last layoffs of the restructuring program.
Tracking Cisco revenues
Lenovo earnings soar 54%, revenues climb 44% to record $8.4B
The world's No. 2 PC maker is confident of closing in on the top spot in PC sales as it reported strong sales growth across all major markets even as it focuses more attention on the burgeoning smartphone and mobile Internet market. Analysts like what they see.
Tracking Lenovo's growth
Siemens, GSK joint venture team for personalized diagnostic drug tests
An HIV/AIDS treatment developed by GlaxoSmithKline is now being studied with Siemens to develop companion diagnostics that doctors can use to select patients appropriate for the treatment.
Tech briefs: New Clinipace exec; Pfizer picks Biologics; Bronto marketing whitepaper; new Telit deal; ChannelAdvisor client win; Mariner training
Triangle Capital looks to raise $67M in stock offering
The Raleigh-based firm focuses on lower middle market companies, which the firm defines as companies with revenues between $10 million and $100 million and earnings between $3 and $20 million.
Co-founder of CoLucid Pharmaceuticals in Durham dies
Dr. James White, a long-time pharmaceutical executive, launched CoLucid in 2005 along with Art Pappas of Pappas Ventures in Durham.
3-D virtualization could boost medical device development
two professors at the University of Minnesota have come up with a 3-D visualization device that aims to revolutionize how medical devices are designed and tested, thereby shortening R&D cycles and the costs associated.
3-D journey of the body
Telecom news: iPhone boosts Sprint; Nokia cutting jobs
Sprint's losses soar even as number of subscribers grows. Meanwhile, Nokia says it will cut 4,000 more jobs and quit manufacturing phones in Europe.
Tale of two drug giants: GSK's pipeline full, AstraZeneca's dwindles
Analysis: While AstraZeneca cuts, GSK is putting itself in a position to discover, develop and position for approval of a wider array of potential drug candidates. It's a strategy that should pay off in the best of times, and the worst of times.
Drug research